BCL2L1 and prostate cancer: In a recent study oflung cancers with wild-type EGFR, the activation of EGFR upregulated SOX2, therebydecreasing apoptosis through BCL2L1, a phenomenon that was notably absent inEGFR-mutant lung cancers (Chou et al., 2013).A similar pathway was reported in a prostate cancer cell line, also with wild-typeEGFR (Rybak and Tang, 2013).